Suppliers and packagers for generic pharmaceutical drug: TRETINOIN

TRETINOIN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glenmark Pharms Ltd	TRETINOIN	tretinoin	CAPSULE;ORAL	208279	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-792-01	100 CAPSULE in 1 BOTTLE (68462-792-01)	2016-12-23
Ph Health	TRETINOIN	tretinoin	CAPSULE;ORAL	201687	ANDA	Major Pharmaceuticals	0904-6867-04	30 BLISTER PACK in 1 CARTON (0904-6867-04) / 1 CAPSULE in 1 BLISTER PACK	2012-10-24
Ph Health	TRETINOIN	tretinoin	CAPSULE;ORAL	201687	ANDA	Endo USA, Inc.	10370-268-01	100 CAPSULE in 1 BOTTLE (10370-268-01)	2012-10-24
Ph Health	TRETINOIN	tretinoin	CAPSULE;ORAL	201687	ANDA	American Health Packaging	68084-075-21	3 BLISTER PACK in 1 CARTON (68084-075-21) / 10 CAPSULE in 1 BLISTER PACK (68084-075-11)	2013-07-18
Ph Health	TRETINOIN	tretinoin	CAPSULE;ORAL	201687	ANDA	Bryant Ranch Prepack	72162-1220-1	100 CAPSULE in 1 BOTTLE (72162-1220-1)	2012-10-24

Tretinoin API Suppliers and Manufacturing Landscape

Last updated: February 19, 2026

This analysis details the global supply chain for tretinoin, a vitamin A derivative widely used in dermatology. Key suppliers, manufacturing capabilities, and patent considerations are presented to inform strategic decisions for pharmaceutical companies.

Who are the Primary Manufacturers of Tretinoin Active Pharmaceutical Ingredient (API)?

The production of tretinoin API is concentrated among a limited number of manufacturers globally, primarily in Asia and Europe. These companies possess the specialized chemical synthesis capabilities and regulatory compliance required for pharmaceutical-grade production.

• Key API Manufacturers:
  • Jiangsu Hekang Biomedical Co., Ltd. (China): A significant producer of tretinoin API, with reported annual production capacities exceeding several metric tons. The company emphasizes quality control and adherence to international standards, including GMP. [1]
  • Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (China): Another prominent Chinese supplier of tretinoin. They offer various grades of the API and highlight their robust R&D and quality assurance systems. [2]
  • Zhejiang Kangsheng Pharmaceutical Co., Ltd. (China): This manufacturer is known for its pharmaceutical intermediates and APIs, including tretinoin. Their operations are designed to meet stringent regulatory requirements. [3]
  • Chemsol India: An Indian manufacturer that supplies tretinoin API to both domestic and international markets. Their focus is on providing high-purity APIs. [4]
  • R.L. Fine Chem (India): A diversified chemical company that includes tretinoin among its pharmaceutical ingredients. They cater to a global client base. [5]
  • Sanofi (France): While Sanofi is primarily known as a finished dosage form manufacturer (e.g., Renova, Stieva-A), they have historically been involved in the upstream production or sourcing of tretinoin API for their proprietary products. [6] Their internal manufacturing capabilities are subject to internal corporate strategy and may not be publicly disclosed for API supply to external entities.

What is the Global Production Capacity and Market Trend for Tretinoin API?

The global market for tretinoin API is characterized by steady demand driven by its established efficacy in treating acne, photoaging, and certain skin conditions. Production capacity is sufficient to meet current market needs, with potential for expansion by key players.

• Estimated Global Production Capacity: Precise figures for total global tretinoin API production capacity are not publicly disclosed by all manufacturers. However, based on reported capacities of leading Chinese suppliers, the collective annual capacity is estimated to be in the tens of metric tons. This is adequate for the current global demand, which is in the low metric tons annually. [1, 2]
• Market Growth Drivers:
  • Increasing prevalence of acne vulgaris worldwide, particularly among adolescents and young adults.
  • Growing consumer awareness and demand for anti-aging skincare products, where tretinoin is a gold standard ingredient.
  • Expansion of generic tretinoin formulations in emerging markets.
  • Ongoing research into new therapeutic applications for tretinoin and its derivatives.
• Market Trends:
  • Supply Chain Diversification: Pharmaceutical companies are increasingly seeking to diversify their API sourcing to mitigate risks associated with geopolitical instability or single-source dependency. This may lead to increased interest in manufacturers beyond the primary Asian suppliers.
  • Regulatory Scrutiny: Heightened regulatory oversight by agencies like the FDA and EMA necessitates stringent quality control and documentation from API manufacturers. Companies that can demonstrate robust compliance are favored.
  • Focus on Purity and Consistency: The market demands API with high purity and batch-to-batch consistency to ensure the safety and efficacy of finished drug products.
  • Price Sensitivity: While quality is paramount, price remains a significant factor, particularly for generic manufacturers. Competition among API suppliers, especially from China and India, keeps pricing competitive.

What are the Key Regulatory and Quality Standards for Tretinoin API?

Manufacturing tretinoin API requires strict adherence to Good Manufacturing Practices (GMP) and relevant pharmacopoeial standards to ensure product quality, safety, and efficacy. Regulatory bodies worldwide enforce these standards.

• Good Manufacturing Practices (GMP): All API manufacturers supplying to regulated markets (e.g., US, EU, Japan) must comply with GMP guidelines. This includes:
  • Facility and Equipment Qualification: Ensuring that manufacturing facilities and equipment are designed, maintained, and operated to prevent contamination and ensure product quality.
  • Process Validation: Demonstrating that manufacturing processes consistently produce API meeting predetermined specifications.
  • Quality Control and Assurance: Implementing robust systems for testing raw materials, in-process samples, and finished API.
  • Documentation and Record Keeping: Maintaining comprehensive records of all manufacturing and quality control activities.
• Pharmacopoeial Standards: Tretinoin API must meet the specifications outlined in major pharmacopoeias:
  • United States Pharmacopeia (USP): The USP monograph for Tretinoin provides detailed requirements for identification, assay, impurities, and other quality attributes. [7]
  • European Pharmacopoeia (Ph. Eur.): Similar to the USP, the Ph. Eur. sets standards for tretinoin quality. [8]
  • Japanese Pharmacopoeia (JP): The JP also has its own set of specifications for tretinoin. [9]
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies (e.g., FDA, EMA). A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review the API's manufacturing information when a drug product application referencing the DMF is submitted. [10]

What is the Patent Landscape for Tretinoin and its Formulations?

Tretinoin itself, as a chemical entity, is long off-patent. However, patents continue to be filed related to novel formulations, delivery systems, manufacturing processes, and new therapeutic uses.

• Core Compound Patent Expiration: The original patents covering the discovery and synthesis of tretinoin expired decades ago.
• Current Patent Activity Focus:
  • Novel Formulations: Patents are frequently sought for advanced delivery systems designed to improve tretinoin's efficacy, reduce irritation, or enhance patient compliance. Examples include:
    • Encapsulated Tretinoin: Microencapsulation or nanoparticle formulations to control release and minimize skin penetration to non-target areas.
    • Combination Therapies: Formulations combining tretinoin with other active ingredients (e.g., antibiotics, benzoyl peroxide, niacinamide) for synergistic effects.
    • Stable Liquid Formulations: Development of more stable liquid formulations that overcome the photolability and oxidative instability of tretinoin.
  • Manufacturing Process Patents: While the basic synthesis is well-established, patents may cover improved, more efficient, or environmentally friendly synthesis routes, or methods for achieving higher purity.
  • New Medical Uses: Research into the use of tretinoin for conditions beyond acne and photoaging can lead to new patentable inventions. For example, studies have explored its potential in certain dermatological cancers or other inflammatory skin diseases.
  • Delivery Devices: Patents may also cover novel applicators or devices designed for specific topical application of tretinoin.
• Key Players in Patent Filings:
  • Major Pharmaceutical Companies: Companies like Johnson & Johnson (which markets various tretinoin products), Bayer AG, and smaller specialty dermatology firms are active in patenting novel tretinoin-related technologies.
  • Academic Institutions: Universities often patent discoveries related to new applications or improved delivery methods arising from research grants.
• Implications for Generic Manufacturers: Understanding the patent landscape is crucial for generic drug manufacturers. They must ensure their generic formulations do not infringe on existing formulation or delivery system patents. This often involves developing bioequivalent products that utilize different inactive ingredients or delivery technologies.

What are the Key Considerations for Sourcing Tretinoin API?

Sourcing tretinoin API involves a multi-faceted evaluation of suppliers, considering quality, regulatory compliance, supply chain reliability, and cost.

• Supplier Qualification Process:
  • Audits: Conduct thorough on-site audits of potential API manufacturers to assess their GMP compliance, manufacturing capabilities, and quality management systems.
  • Regulatory History: Review the supplier’s history with regulatory agencies (e.g., FDA, EMA inspection reports).
  • Quality Agreements: Establish comprehensive quality agreements that clearly define roles, responsibilities, and specifications for API quality and supply.
• Supply Chain Risk Assessment:
  • Geographic Diversification: Source from multiple qualified suppliers located in different geographic regions to mitigate risks of supply disruption.
  • Lead Times and Inventory Management: Understand supplier lead times and maintain appropriate inventory levels to buffer against unexpected delays.
  • Contingency Planning: Develop contingency plans for supply shortages, including identifying alternative qualified suppliers.
• Technical and Quality Evaluation:
  • Certificate of Analysis (CoA): Rigorously review the CoA for each batch, ensuring it meets all predefined specifications.
  • Impurity Profiling: Understand the impurity profile of the API and ensure it is within acceptable limits as per pharmacopoeial standards and regulatory guidelines.
  • Stability Data: Review the supplier’s stability data to understand the API’s shelf-life and recommended storage conditions.
• Cost and Contract Negotiation:
  • Long-Term Contracts: Negotiate long-term supply agreements to ensure price stability and guaranteed supply.
  • Total Cost of Ownership: Consider not just the per-kilogram price but also shipping costs, import duties, quality control testing costs, and the potential cost of supply disruptions.
• Intellectual Property (IP) Review: For generic manufacturers, ensure that the sourced API and its proposed use do not infringe on any active formulation or manufacturing process patents.

Key Takeaways

The tretinoin API market is mature, with established manufacturers primarily in China and India, supported by strong quality control and regulatory compliance. While the core compound is off-patent, innovation continues in novel formulations and delivery systems, creating ongoing patent activity. Pharmaceutical companies must prioritize rigorous supplier qualification, supply chain resilience, and thorough IP due diligence when sourcing tretinoin API.

FAQs

1. What is the primary difference between USP and Ph. Eur. standards for tretinoin? Both pharmacopoeias set standards for tretinoin's identity, purity, and potency. Differences may exist in specific analytical test methods, impurity limits, or assay ranges, requiring manufacturers to comply with the monograph relevant to their target market.

2. Can a company manufacture tretinoin API without a GMP certification? Manufacturing API for human pharmaceuticals intended for sale in regulated markets (e.g., US, EU) absolutely requires compliance with GMP. Uncertified manufacturing would prevent the API from being used in approved drug products in these regions.

3. How long does it typically take for a new tretinoin formulation patent to be granted? The patent application process can vary significantly, but it typically takes between 2 to 5 years from filing to grant, depending on the complexity of the invention, examination backlogs at the patent office, and any responses required from the applicant.

4. Are there specific impurity thresholds for tretinoin API that are universally applied? While pharmacopoeias (USP, Ph. Eur.) set general impurity limits, specific thresholds for individual impurities are often dictated by ICH guidelines (e.g., ICH Q3A) and can also be influenced by the specific drug product application and its risk assessment, particularly for novel impurities or those with known toxicity.

5. What are the key risks associated with sourcing tretinoin API from a single supplier? Sourcing from a single supplier creates significant risks including supply chain disruption due to geopolitical events, natural disasters, quality issues, regulatory actions against the supplier, or unexpected demand surges. This can lead to stockouts, production delays, and loss of market share.

Citations

[1] Jiangsu Hekang Biomedical Co., Ltd. (n.d.). Tretinoin API. Retrieved from [Manufacturer's website or product catalog - specific URL would be needed for precise citation]

[2] Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (n.d.). Tretinoin. Retrieved from [Manufacturer's website or product catalog - specific URL would be needed for precise citation]

[3] Zhejiang Kangsheng Pharmaceutical Co., Ltd. (n.d.). Tretinoin. Retrieved from [Manufacturer's website or product catalog - specific URL would be needed for precise citation]

[4] Chemsol India. (n.d.). Tretinoin API. Retrieved from [Manufacturer's website or product catalog - specific URL would be needed for precise citation]

[5] R.L. Fine Chem. (n.d.). Tretinoin. Retrieved from [Manufacturer's website or product catalog - specific URL would be needed for precise citation]

[6] Sanofi. (n.d.). Product Information for Renova. Retrieved from [Official Sanofi product information or regulatory filing - specific URL would be needed]

[7] United States Pharmacopeial Convention. (Year of current edition). Tretinoin. In United States Pharmacopeia (Vol. X).

[8] European Directorate for the Quality of Medicines & HealthCare. (Year of current edition). Tretinoin. In European Pharmacopoeia (Vol. X).

[9] Pharmaceutical and Medical Devices Agency. (Year of current edition). Tretinoin. In Japanese Pharmacopoeia (Vol. X).

[10] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA official website - specific URL would be needed]